Pharmacotherapy of personality disorders

Journal of Mental Health

Volumn 16, Issue 1, 2007, Pages 5-50

  Triebwasser, Joseph ^a,b   Siever, Larry J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antisocial; Avoidant; Axis II; Borderline; Personality disorder; Pharmacotherapy; Schizotypal

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BROFAROMINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; DESIPRAMINE; FLUOXETINE; FLUPENTIXOL; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; ICOSAPENTAENOIC ACID ETHYL ESTER; IMIPRAMINE; LITHIUM; LOXAPINE; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OLANZAPINE; OXAZEPAM; PAROXETINE; PHENELZINE; PHENYTOIN; PLACEBO; TIOTIXENE; TRANYLCYPROMINE; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROATE SEMISODIUM;

AVOIDANT PERSONALITY DISORDER; BORDERLINE STATE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; HOSTILITY; HUMAN; IMPULSIVENESS; IRRITABILITY; MEDLINE; PARANOIA; PERSONALITY DISORDER; PSYCHOPATHY; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOTYPAL PERSONALITY DISORDER; SIDE EFFECT; SUICIDAL IDEATION; SYMPTOM;

EID: 33847182800     PISSN: 09638237     EISSN: 13600567     Source Type: Journal    
DOI: 10.1080/09638230601182078     Document Type: Review

References (177)

1. Aberg-Wistedt, A., Agren, H., Ekselius, L., Bengtsson, F., & Akerblad, A.C. (2000). Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. Journal of Clinical Psychopharmacology, 20, 645-652.
2. Akiskal, H. S. (2004). Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. Acta Psychiatrica Scandinavica, 110, 401-407.
3. Aldenkamp, A. P., Arends, J., Bootsma, H. P. R., Diepman, L., Hulsman, J., Lambrechts, D., Leenen, L., Majoie, M., Schellekens, A., & de Vocht, J. (2002). Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia, 43, 19-26.
4. American Psychiatric Association. (2001). Practice guideline for the treatment of patients with borderline personality disorder. American Journal of Psychiatry, 158 (October Suppl.), 1-52.
5. Barratt, E. S., Kent, T. A., Bryant, S. G., & Felthous, A. R. (1991). A controlled trial of phenytoin in impulsive aggression. Journal of Clinical Psychopharmacology, 11, 388-389.
6. Barratt, E. S., Stanford, M. S., Felthous, A. R., & Kent, T. A. (1997). The effects of phenytoin on impulsive and premeditated aggression: a controlled study. Journal of Clinical Psychopharmacology, 17, 341-349.
7. Battaglia, J., Wolff, T. K., Wagner-Johnson, D. S., Rush, A. J., Carmody, T. J., & Basco, M. R. (1999). Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department. International Clinical Psychopharmacology, 14, 361-372.
8. Bender, D. S., Dolan, R. T., Skodol, A. E., Sanislow, C. A., Dyck, I. R., McGlashan, T. H., Shea, M. T., Zanarini, M. C., Oldham, J. M., & Gunderson, J. G. (2001). Treatment utilization by patients with personality disorders. American Journal of Psychiatry, 158, 295-302.
9. Berger, P., Sachs, G., Amering, M., Holzinger, A., Bankier, B., & Katschnig, H. (2004). Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder. Journal of Affective Disorders, 80, 75-78.
10. Bernstein, D. P., Kasapis, C., Bergman, A., Weld, E., Mitropoulou, V., Horvath, T., Klar, H. M., Silverman, J., & Siever, L. J. (1997). Assessing axis II disorders by informant interview. Journal of Personal Disorders, 11, 158-167.
11. Bieling, P. J., MacQueen, G. M., Marriot, M. J., Robb, J. C., Begin, H., Joffe, R. T., & Young, L. T. (2003). Longitudinal outcome in patients with bipolar disorder assessed by life-charting is influenced by DSM-IV personality disorder symptoms. Bipolar Disorders, 5, 14-21.
12. Black, K. J., & Sheline Y. I. (1997). Personality disorder scores improve with effective pharmacotherapy of depression. Journal of Affective Disorders, 43, 11-18.
13. Bogenschutz, M. P., & Nurnberg, G. H. (2004). Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 104-109.
14. Bohus, M. J., Landwehrmeyer, G. B., Stiglmayr, C. E., Limberger, M. F., Bohme, R., & Schmahl, C. G. (1999). Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an openlabel trial. Journal of Clinical Psychiatry, 60, 598-603.
15. Bohus, M., Schmahl, C., & Lieb, K. (2004). New developments in the neurobiology of borderline personality disorder. Current Psychiatry Reports, 6, 43-50.
16. Bolton, S., & Gunderson, J. G. (1996). Distinguishing borderline personality disorder from bipolar disorder: differential diagnosis and implications. American Journal of Psychiatry, 153, 1202-1207.
17. Brambilla, P., Soloff, P. H., Sala, M., Nicoletti, M. A., Keshavan, M. S., & Soares, J. C. (2004). Anatomical MRI study of borderline personality disorder patients. Psychiatry Research, 131, 125-133.
18. Brendel, G. R., Stern, E., & Silbersweig, D. A. (2005). Defining the neurocircuitry of borderline personality disorder: Functional neuroimaging approaches. Development and Psychopathology, 17, 1197-1206.
19. Cavedini, P., Erzegovesi, S., Ronchi, P., & Bellodi, L. (1997). Predictive value of Obsessive-Compulsive Personality Disorder in antiobsessional pharmacological treatment. European Neuropsychopharmacology, 7, 45-49.
20. Coccaro, E. F., & Kavoussi, R. J. (1997). Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Archives of General Psychiatry, 54, 1081-1088.
21. Coccaro, E. F., Kavoussi, R. J., & Hauger, R. L. (1995). Physiological responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder. International Clinical Psychopharmacology, 10, 177-179.
22. Coccaro, E. F., Kavoussi, R. J., & Hauger, R. L. (1997). Serotonin function and antiaggressive response to fluoxetine: A pilot study. Biological Psychiatry, 42, 546-552.
23. Coccaro, E. F., Siever, L. J., Klar, H. M., Maurer, G., Cochrane, K., Cooper, T. B., Mohs, R. C., & Davis, K. L. (1989). Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Archives of General Psychiatry, 46, 587-599.
24. Cohen, L. J., Kingston, P., Bell, A., Kwon, J., Aronowitz, B., & Hollander, E. (2000). Comorbid personality impairment in body dysmorphic disorder. Comprehensive Psychiatry, 41, 4-12.
25. Cornelius, J. R., Soloff, P. H., Perel, J. M., & Ulrich R. F. (1993). Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. American Journal of Psychiatry, 150, 1843-1848.
26. Cowdry, R. W., & Gardner, D. L. (1988). Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of General Psychiatry, 45, 111-119.
27. de la Fuente, J. M., & Lotstra, F. (1994). A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology, 4, 479-486.
28. Ekselius, L., & von Knorring, L. (1998). Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. International Clinical Psychopharmacology, 13, 205-211.
29. Enns, M. W., Swenson, J. R., McIntyre, R. S., Swinson, R. P., Kennedy, S. H., & CANMAT Depression Work Group. (2001). Clinical guidelines for the treatment of depressive disorders: vii. comorbidity. Canadian Journal of Psychiatry, 46 (Suppl. 1), 77S-90S.
30. Evenden, J. (1999). Impulsivity: a discussion of clinical and experimental findings. Journal of Psychopharmacology, 13, 180-192.
31. Fahlén, T. (1995). Personality traits in social phobia, II: changes during drug treatment. Journal of Clinical Psychiatry, 56, 569-573.
32. Faltus, F. J. (1984). The positive effect of alprazolam in the treatment of three patients with borderline personality disorder. American Journal of Psychiatry, 141, 802-803.
33. Fava, M., Bouffides, E., Pava, J. A., McCarthy, M. K., Steingard, R. J., & Rosenbaum, J. F. (1994). Personality disorder comorbidity with major depression and response to fluoxetine treatment. Psychotherapy and Psychosomatics, 62, 160-167.
34. Fava, M., Farabaugh, A. H., Sickinger, A. H., Wright, E., Alpert, J. E., Sonawalla, S., Nierenberg, A. A., & Worthington, J. J. 3rd. (2002). Personality disorders and depression. Psychological Medicine, 32, 1049-1057.
35. Frankenburg, F. R., & Zanarini, M. C. (2002). Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry, 63, 442-446.
36. Friedel, R. O. (2004). Dopamine dysfunction in borderline personality disorder: A hypothesis. Neuropsychopharmacology, 29, 1029-1039.
37. Gardner, D. L., & Cowdry, R. W. (1985). Alprazolam-induced dyscontrol in borderline personality disorder. American Journal of Psychiatry, 142, 98-100.
38. Gardner, D. L., & Cowdry, R. W. (1986a). Development of melancholia during carbamazepine treatment in borderline personality disorder. Journal of Clinical Psychopharmacology, 6, 236-239.
39. Gardner, D. L., & Cowdry, R. W. (1986b). Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. American Journal of Psychiatry, 143, 519-522.
40. Gasperini, M., Scherillo, P., Manfredonia, M. G., Franchini, L., & Smeraldi, E. (1993). A study of relapses in subjects with mood disorder on lithium treatment. European Neuropsychopharmacology, 3, 103-110.
41. Geddes, J. R., Burgess, S., Hawton, K., Jamison, K., & Goodwin, G. M. (2004). Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. American Journal of Psychiatry, 161, 217-222.
42. Goldberg, S. C., Schulz, S. C., Resnick, R. J., Hamer, R. M., & Schulz, P. M. (1987). Differential prediction of response to thiothixene and placebo in borderline and schizotypal personality disorders. Psychopharmacology Bulletin, 23, 342-346.
43. Goldberg, S. C., Schulz, S. C., Schulz, P. M., Resnick, R. J., Hamer, R. M., & Friedel, R. O. (1986). Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Archives of General Psychiatry, 43, 680-686.
44. Gollan, J. K., Lee, R., & Coccaro, E. F. (2005). Development, psychopathology and neurobiology of aggression. Development and Psychopathology, 17, 1151-1171.
45. Goodman, M., Mitropoulou, V., New, A. S., Koenigsberg, H. W., & Siever, L. J. (2000). Frontal cortex dysfunction and subcortical dopaminergic activity in schizophrenia spectrum. Biological Psychiatry, 47, S34.
46. Goodman, M., & New, A. (2000). Impulsive aggression in borderline personality disorder. Current Psychiatry Reports, 2, 56-61.
47. Goodman, M., New, A., & Siever, L. (2004). Trauma, genes, and the neurobiology of personality disorders. Annals of the New York Academy of Sciences, 1032, 104-116.
48. Griengl, H., Sendera, A., & Dantendorfer, K. (2001). Naltrexone as a treatment of self-injurious behavior-a case report. Acta Psychiatrica Scandinavica, 103, 234-236.
49. Gross-Isseroff, R., Dillon, K. A., Israeli, M., & Biegon, A. (1990). Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Research, 530, 312-316.
50. Harvey, P. D., & Keefe, R. S. (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry, 158, 176-184.
51. Heinze, M., Andreae, D., & Grohmann, R. (2005). Pharmacotherapy of personality disorders in German speaking countries: State and changes in the last decade. Pharmacopsychiatry, 38, 201-205.
52. Henry, C., Mitropoulou, V., New, A. S., Koenigsberg, H. W., Silverman, J., & Siever, L. J. (2001). Affective instability and impulsivity in borderline personality and bipolar II disorders: Similarities and differences. Journal of Psychiatric Research, 35, 307-312.
53. Higgins, G. A., Enderlin, M., Haman, M., & Fletcher, P. J. (2003). The 5-HT2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism. Psychopharmacology (Berlin), 170, 309-319.
54. Hirschfeld, R. M., Russell, J. M., Delgado, P. L., Fawcett, J., Friedman, R. A., Harrison, W. M., Koran, L. M., Miller, I. W., Thase, M. E., Howland, R. H., Connolly, M. A., & Miceli, R. J. (1998). Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. Journal of Clinical Psychiatry, 59, 669-675.
55. Hollander, E., Allen, A., Lopez, R. P., Bienstock, C. A., Grossman, R., Siever, L. J., Merkatz, L., & Stein, D. J. (2001). A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Journal of Clinical Psychiatry, 62, 199-203.
56. Hollander, E., Swann, A. C., Coccaro, E. F., Jiang, P., & Smith, T. B. (2005). Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. American Journal of Psychiatry, 162, 621-624.
57. Hollander, E., Tracy, K. A, Swann, A. C., Coccaro, E. F., McElroy, S. L., Wozniak, P., Sommerville, K. W., & Nemeroff, C. B. (2003). Divalproex in the treatment of impulsive aggression: Efficacy in cluster B personality disorders. Neuropsychopharmacology, 28, 1186-1197.
58. Houston, R. J., Bauer, L. O., & Hesselbrock, V. M. (2004). Effects of borderline personality disorder features and a family history of alcohol or drug dependence on P300 in adolescents. International Journal of Psychophysiology, 53, 57-70.
59. Hymowitz, P., Frances, A., Jacobsberg, L. B., Sickles, M., & Hoyt, R. (1986). Neuroleptic treatment of schizotypal personality disorders. Comprehensive Psychiatry, 27, 267-271.
60. Jensen, H. V., & Andersen, J. (1989). An open, noncomparative study of amoxapine in borderline disorders. Acta Psychiatrica Scandinavica, 79, 89-93.
61. Joffe, R. T., & Regan, J. J. (1989). Personality and response to tricyclic antidepressants in depressed patients. Journal of Nervous and Mental Disease, 177, 745-749.
62. Joyce, P. R., Mulder, R. T., Luty, S. E., McKenzie, J. M., Sullivan, P. F., & Cloninger, R. C. (2003). Borderline personality disorder in major depression: Symptomatology, temperament, character, differential drug response, and 6-month outcome. Comprehensive Psychiatry, 44, 35-43.
63. Juengling, F. D., Schmahl, C., Hesslinger, B., Ebert, D., Bremner, J. D., Gostomzyk, J., Bohus, M., & Lieb, K. (2003). Positron emission tomography in female patients with borderline personality disorder. Journal of Psychiatric Research, 37, 109-115.
64. Kato, M., Ikenaga, Y., Wakeno, M., Okugawa, G., Nobuhara, K., Fukuda, T., Fukuda, K., Azuma, J., & Kinoshita, T. (2005). Controlled clinical comparison of paroxetinee and fluvoxamine considering the serotonin transporter promoter polymorphism. International Clinical Psychopharmacology, 20, 151-156.
65. Kayser, A., Robinson, D. S., Nies, A., & Howard, D. (1985). Response to phenelzine among depressed patients with features of hysteroid dysphoria. American Journal of Psychiatry, 142, 486-488.
66. Kemperman, I., Russ, M. J., & Shearin, E. (1997). Self-injurious behavior and mood regulation in borderline patients. Journal of Personality Disorders, 11, 146-157.
67. Keshavan, M., Shad, M., Soloff, P., & Schooler, N. (2004). Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophrenia Research, 71, 97-101.
68. Koenigsberg, H. W., Reynolds, D., Goodman, M., New, A. S., Mitropoulou, V., Trestman, R. L., Silverman, J., & Siever, L .J. (2003). Risperidone in the treatment of schizotypal personality disorder. Journal of Clinical Psychiatry, 64, 628-634.
69. Kool, S., Dekker, J., Duijsens, I. J., de Jonghe, F., & Puite, B. (2003). Changes in personality pathology after pharmacotherapy and combined therapy for depressed patients. Journal of Personality Disorders, 17, 60-72.
70. Kool, S., Schoevers, R., de Maat, S., Van, R., Molenaar, P., Vink, A., & Dekker, J. (2005). Efficacy of pharmacotherapy in depressed patients with and without personality disorders: A systematic review and metaanalysis. Journal of Affective Disorders, 88, 269-278.
71. Kugaya, A., Sanacora, G., Staley, J. K., Malison, R. T., Bozkurt, A., Khan, S., Anand, A., van Dyck, C. H., Baldwin, R. M., Seibyl, J. P., Charney, D., & Innis, R. B. (2004). Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biological Psychiatry, 56, 497-502.
72. Kumor, K. M., Haertzen, C. A., Johnson, R. E., Kocher, T., & Jasinski, D. (1986). Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. Journal of Pharmacology and Experimental Therapeutics, 238, 960-968.
73. Lee, M.-S., Lee, H. Y., Lee, H.-J., & Ryu, S.-H. (2004). Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatric Genetics, 14, 111-115.
74. Leone, N. F. (1982). Response of borderline patients to loxapine and chlorpromazine. Journal of Clinical Psychiatry, 43, 148-150.
75. Lestra, C., d'Amato, T., Ghaemmaghami, C., Perret-Liaudet, A., Broyer, M., Renaud, B., Dalery, J., & Chamba, G. (1998). Biological parameters in major depression: effects of paroxetine, viloxazine, moclobemide, and electroconvulsive therapy. Relation to early clinical outcome. Biological Psychiatry, 44, 274-280.
76. Levitt, J. J., Westin, C. F., Nestor, P. G., Estepar, R. S., Dickey, C. C., Voglmaier, M. M., Seidman, L. J., Kikinis, R., Jolesz, F. A., McCarley, R. W., & Shenton, M. E. (2004). Shape of caudate nucleus and its cognitive correlates in neuroleptic-naive schizotypal personality disorder. Biological Psychiatry, 55, 177-184.
77. Liebowitz, M. R., & Klein, D. F. (1981). Interrelationship of hysteroid dysphoria and borderline personality disorder. Psychiatric Clinics of North America, 4, 67-87.
78. Links, P. S, Steiner, M., Boiago, I., & Irwin, D. (1990). Lithium therapy for borderline patients: preliminary findings. Journal of Personality Disorders, 4, 173-181.
79. Lion, J. R. (1979). Benzodiazepines in the treatment of aggressive patients. Journal of Clinical Psychiatry, 40, 70-71.
80. Loranger, A. W., Lenzenweger, M. F., Gartner, A. F., Susman, V. L., Herzig, J., Zammit, G. K., Gartner, J. D., Abrams, R. C., & Young, R. C. (1991). Trait-state artifacts and the diagnosis of personality disorders. Archives of General Psychiatry, 48, 720-728.
81. Makela, E. H., Moeller, K. E., Fullen, J. E., & Gunel, E. (2006). Medication utilization patterns and methods of suicidality in borderline personality disorder. Annals of Pharmacotherapy, 40, 49-52.
82. Malone, K. M., Corbitt, E. M., Li, S., &Mann, J. J. (1996). Prolactin response to fenfluramine and suicide attempt lethality in major depression. British Journal of Psychiatry, 168, 324-329.
83. Marek, G. J., Martin-Ruiz, R., Abo, A., & Artigas, F. (2005). The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology, 30, 2205-2215.
84. Markovitz, P. J., Calabrese, J. R., Schulz, S. C., & Meltzer, H. Y. (1991). Fluoxetine in the treatment of borderline and schizotypal personality disorders. American Journal of Psychiatry, 148, 1064-1067.
85. Mavissakalian, M., Hamann, M. S., & Jones, B. (1990). DSM-III personality disorders in obsessive-compulsive disorder: changes with treatment. Comprehensive Psychiatry, 31, 432-437.
86. McGee, M. D. (1997). Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. Journal of Clinical Psychiatry, 58, 32-33.
87. McGlashan, T. H., Grilo, C. M., Skodol, A. E., Gunderson, J. G., Shea, M. T., Morey, L. C., Zanarini, M. C., & Stout, R. L. (2000). The Collaborative Longitudinal Personality Disorders Study: Baseline Axis I/II and II/II diagnostic co-occurrence. Acta Psychiatrica Scandinavica, 102, 256-264.
88. Mehlman, P. T., Higley, J. D., Faucher, I., Lilly, A. A., Taub, D. M., Vickers, J., Suomi, S. J., & Linnoila, M. (1994). Low CSF 5-HIAA concentrations and severe aggression and impaired impulse control in nonhuman primates. American Journal of Psychiatry, 151, 1485-1491.
89. Minzenberg, M. J., Grossman, R., New, A. S., Mitropoulou, V., Yehuda, R., Goodman, M., Reynolds, D. A., Silverman, J. M., Coccaro, E. F., Marcus, S., & Siever, L. J. (2006). Blunted hormone responses to ipsapirone are associated with trait impulsivity in personality disorder patients. Neuropsychopharmacology, 31, 197-203.
90. Montgomery, S. A., & Montgomery, D. (1982). Pharmacological prevention of suicidal behavior. Journal of Affective Disorders, 4, 291-298.
91. Montgomery, S. A., Roy, D., & Montgomery, D. B. (1983). The prevention of recurrent suicidal acts. British Journal of Clinical Pharmacology, 15, 183S-188S.
92. Mulder, R. T. (2002). Personality pathology and treatment outcome in major depression: A review. American Journal of Psychiatry, 159, 359-371.
93. Mulder, R. T., Joyce, P. R., & Luty, S. E. (2003). The relationship of personality disorders to treatment outcome in depressed outpatients. Journal of Clinical Psychiatry, 64, 259-264.
94. Nelson, J. C., Mazure, C. M., & Jatlow, P. I. (1994). Characteristics of desipramine-refractory depression. Journal of Clinical Psychiatry, 55, 12-19.
95. New, A. S., Hazlett, E. A., Buchsbaum, M. S., Goodman, M., Reynolds, D., Mitropoulou, V., Sprung, L., Shaw, R. B. Jr., Koenigsberg, H., Platholi, J., Silverman, J., & Siever, L. J. (2002). Blunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to meta-chlorophenylpiperazine in impulsive aggression. Archives of General Psychiatry, 59, 621-629.
96. New, A. S., Trestman, R., Mitropoulou, V., Benishay, D. S., Coccaro, E., Silverman, J., & Siever, L. J. (1997). Serotonergic function and self-injurious behavior in personality disorder patients. Psychiatry Research, 69, 17-26.
97. New, A. S., Trestman, R., Mitropoulou V., Goodman, M., Koenigsberg, H., Silverman, J., & Siever, L. J. (2004). Low prolactin response to fenfluramine in impulsive aggression. Journal of Psychiatric Research, 38, 223-230.
98. Nickel, M. K., Nickel, C., Kaplan, P., Lahmann, C., Muhlbacher, M., Tritt, K., Krawczyk, J., Leiberich, P. K., Rother, W. K., & Loew, T. H. (2005). Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study. Biological Psychiatry, 57, 495-499.
99. Nickel, M. K., Nickel, C., Mitterlehner, F. O., Tritt, K., Lahmann, C., Leiberich, P. K., Rother, W. K., & Loew, T. H. (2004). Topiramate treatment of aggression in female borderline personality disorder patients: A doubleblind, placebo-controlled study. Journal of Clinical Psychiatry, 65, 1515-1519.
100. Noyes, R. Jr., Reich, J., Christiansen, J., Suelzer, M., Pfohl, B., & Coryell, W. A. (1990). Outcome of panic disorder. Relationship to diagnostic subtypes and comorbidity. Archives of General Psychiatry, 47, 809-818.
101. Noyes, R. Jr., Reich, J. H., Suelzer, M., & Christiansen, J. (1991). Personality traits associated with panic disorder: Change associated with treatment. Comprehensive Psychiatry, 32, 283-294.
102. Ogiso, Y., Moriya, N., Ikuta, N., Maher-Nishizono, A., Takase, M., Miyake, Y., & Minakawa, K. (1993). Relationship between clinical symptoms and EEG findings in borderline personality disorder. Japanese Journal of Psychiatry and Neurology, 47, 37-46.
103. Oldham, J. M., Bender, D. S., Skodol, A. E., Dyck, I. R., Sanislow, C. A., Yen, S., Grilo, C. M., Shea, M. T., Zanarini,M. C., Gunderson, J. G., & McGlashan, T. H. (2004). Testing an APA practice guideline: Symptom-targeted medication utilization for patients with borderline personality disorder. Journal of Psychiatric Practice, 10, 156-161.
104. Oquendo, M. A., Krunic, A., Parsey, R. V., Milak, M., Malone, K. M., Anderson, A., van Heertum, R. L, & John Mann, J. (2005). Positron emission tomography of regional brain metabolic responses to a serotonergic challenge in major depressive disorder with and without borderline personality disorder. Neuropsychopharmacology, 30, 1163-1172.
105. Papakostas, G. I., Petersen, T. J., Farabaugh, A. H., Murakami, J. L., Pava, J. A., Alpert, J. E., Fava, M., & Nierenberg, A. A. (2003). Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry, 64, 1357-1361.
106. Paris, J. (2004). Borderline or bipolar? Distinguishing borderline personality disorder from bipolar spectrum disorders. Harvard Review of Psychiatry, 12, 140-145.
107. Paris, J. (2005). Borderline personality disorder. Canadian Medical Association Journal, 172, 1579-1583.
108. Parsons, B., Quitkin, F. M., McGrath, P. J., Stewart, J. W., Tricamo, E., Ocepek-Welikson, K., Harrison, W., Rabkin, J. G., Wager, S. G., & Nunes, E. (1989). Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacological Bulletin, 25, 524-534.
109. Paykel, E. S. (2001). Continuation and maintenance therapy in depression. British Medical Bulletin, 57, 145-159.
110. Perez, V., Bel, N., Celada, P., Ortiz, J., Alvarez, E., & Artigas, F. (1998). Relationship between blood serotonergic variables, melancholic traits, and response to antidepressant treatments. Journal of Clinical Psychopharmacology, 18, 222-230.
111. Petersen, T., Hughes, M., Papakostas, G. I., Kant, A., Fava, M., Rosenbaum, J. F., & Nierenberg, A. A. (2002). Treatment-resistant depression and Axis II comorbidity. Psychotherapy and Psychosomatics, 71, 269-274.
112. Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M. (1986). Psychotomimesis mediated by kappa opiate receptors. Science, 233, 774-776.
113. Philipsen, A., Richter, H., Schmahl, C., Peters, J., Rusch, N., Bohus, M., & Lieb, K. (2004a). Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. Journal of Clinical Psychiatry, 65, 1414-1419.
114. Philipsen, A., Schmahl, C., & Lieb, K. (2004b). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry, 37, 196-199.
115. Pitchot, W., Hansenne, M., Pinto, E., Reggers, J., Fuchs, S., & Ansseau, M. (2005). 5-Hydroxytryptamine 1A receptors, major depression, and suicidal behavior. Biological Psychiatry, 58, 854-858.
116. Placidi, G. P., Oquendo, M. A., Malone, K. M., Huang, Y. Y., Ellis, S. P., & Mann, J. J. (2001). Aggressivity, suicide attempts, and depression: Relationship to cerebrospinal fluid monoamine metabolite levels. Biological Psychiatry, 50, 783-791.
117. Posner, M. I., Rothbart, M. K., Vizueta, N., Levy, K. N., Evans, D. E., Thomas, K. M., & Clarkin, J. F. (2002). Attentional mechanisms of borderline personality disorder. Proceedings of the National Academy of Sciences, 99, 16366-16370.
118. Preston, G. A., Marchant, B. K., Reimherr, F. W., Strong, R. E., & Hedges, D. W. (2004). Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. Journal of Affective Disorders, 79, 297-303.
119. Reich, J. H. (1990). Effect of DSM-III personality disorders on outcome of tricyclic antidepressant-treated nonpsychotic outpatients with major or minor depressive disorder. Psychiatry Research, 32, 175-181.
120. Reich J., Noyes, R. Jr., Coryell, W., & O'Gorman, T. W. (1986). The effect of state anxiety on personality measurement. American Journal of Psychiatry, 143, 760-763.
121. Rifkin, A., Quitkin, F., Carrillo, C., Blumberg, A. G., & Klein, D. F. (1972). Lithium carbonate in emotionally unstable character disorder. Archives of General Psychiatry, 27, 519-523.
122. Rinne, T., van den Brink, W., Wouters, L., & van Dyck, R. (2002). SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry, 159, 2048-2054.
123. Roth, A. S., Ostroff, R. B., & Hoffman, R. E. (1996). Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial. Journal of Clinical Psychiatry, 57, 233-237.
124. Rüsch, N., van Elst, L. T., Ludaescher, P., Wilke, M., Huppertz, H. J., Thiel, T., Schmahl, C., Bohus, M., Lieb, K., Hesslinger, B., Hennig, J., & Ebert D. (2003). A voxel-based morphometric MRI study in female patients with borderline personality disorder. Neuroimage, 20, 385-392.
125. Russ, M. J., Campbell, S. S., Kakuma, T., Harrison, K., & Zanine E. (1999). EEG theta activity and pain insensitivity in self-injurious borderline patients. Psychiatry Research, 89, 201-214.
126. Russ, M. J., Roth, S. D., Lerman, A., Kakuma, T., Harrison, K., Shindledecker, R. D., Hull, J., & Mattis, S. (1992). Pain perception in self-injurious patients with borderline personality disorder. Biological Psychiatry, 32, 501-511.
127. Russell, J. M., Kornstein, S. G., Shea, M. T., McCullough, J. P., Harrison, W. M., Hirschfeld, R. M., & Keller, M. B. (2003). Chronic depression and comorbid personality disorders: Response to sertraline versus imipramine. Journal of Clinical Psychiatry, 64, 554-561.
128. Salzman, C., Wolfson, A. N., Schatzberg, A., Looper, J., Henke, R., Albanese, M., Schwartz, J., & Miyawaki, E. (1995). Effects of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology, 15, 23-29.
129. Samuelsson, M., Jokinen, J., Nordstrom, A. L., & Nordstrom, P. (2006). CSF 5-HIAA, suicide intent and hopelessness in the prediction of early suicide in male high-risk suicide attempters. Acta Psychiatrica Scandinavica, 113, 44-47.
130. Sansone, R. A., Rytwinski, D., & Gaither, G. A. (2003). Borderline personality and psychotropic medication prescription in an outpatient psychiatry clinic. Comprehensive Psychiatry, 44, 454-458.
131. Saper, J. R. (2000). Borderline personality, opioids, and naltrexone. Headache, 40, 765-766.
132. Saper, J. R., & Lake, A. E. 3rd. (2002). Borderline personality disorder and the chronic headache patient: Review and management recommendations. Headache, 42, 663-674.
133. Schlaepfer, T. E., Strain, E. C., Greenberg, B. D., Preston, K. L., Lancaster, E., Bigelow, G. E., Barta, P. E., & Pearlson, G. D. (1998). Site of opioid action in the human brain: Mu and kappa agonists' subjective and cerebral blood flow effects. American Journal of Psychiatry, 155, 470-473.
134. Schmahl, C. (2005). Neurobiology of BPD: An update. Presented at Annual Meeting of the American Psychiatric Association, Atlanta, GA.
135. Schmahl, C., Greffrath, W., Baumgartner, U., Schlereth, T., Magerl, W., Philipsen, A., Lieb, K., Bohus, M., & Treede, R. D. (2004). Differential nociceptive deficits in patients with borderline personality disorder and selfinjurious behavior: laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings. Pain, 110, 470-479.
136. Schulz, S. C., Camlin, K. L., Berry, S. A., & Jesberger, J. A. (1999). Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biological Psychiatry, 46, 1429-1435.
137. Serban, G., & Siegel, S. (1984). Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. American Journal of Psychiatry, 141, 1455-1458.
138. Serretti, A., Cusin, C., Rossini, D., Artioli, P., Dotoli, D., & Zanardi, R. (2004). Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics), 129, 36-40.
139. Sheard, M. H. (1971). Effect of lithium on human aggression. Nature, 230, 113-114.
140. Sheard, M. H., Marini, J. L., Bridges, C. I., & Wagner, E. (1976). The effect of lithium on impulsive aggressive behavior in man. American Journal of Psychiatry, 133, 1409-1413.
141. Siever, L. J., Amin, F., Coccaro, E. F., Trestman, R., Silverman, J., Horvath, T. B., Mahon, T. R., Knott, P., Altstiel, L., & Davidson, M. (1993). CSF homovanillic acid in schizotypal personality disorder. American Journal of Psychiatry, 150, 149-151.
142. Siever, L. J., Buchsbaum, M. S., New, A. S., Spiegel-Cohen, J., Wei, T., Hazlett, E. A., Sevin, E., Nunn, M., & Mitropoulou, V. (1999). d,l-fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology, 20, 413-423.
143. Siever, L. J., & Davis, K. L. (1991). A psychobiological perspective on the personality disorders. American Journal of Psychiatry, 148, 1647-1658.
144. Siever, L. J., & Davis, K. L. (2004). The pathophysiology of schizophrenia disorders: Perspectives from the spectrum. American Journal of Psychiatry, 161, 398-413.
145. Simeon, D., Stanley, B., Frances, A., Mann, J. J., Winchel, R., & Stanley, M. (1992). Self-mutilation in personality disorders: psychological and biological correlates. American Journal of Psychiatry, 149, 221-226.
146. Simpson, E. B., Yen, S., Costello, E., Rosen, K., Begin, A., Pistorello, J., & Pearlstein, T. (2004). Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 379-385.
147. Slaap, B. R., & den Boer, J. A. (2001). The prediction of nonresponse to pharmacotherapy in panic disorder: A review. Depression and Anxiety, 14, 112-122.
148. Smith, D. J., Muir, W. J., & Blackwood, D. H. (2004). Is borderline personality disorder part of the bipolar spectrum? Harvard Review of Psychiatry, 12, 133-139.
149. Soderstrom, H., & Forsman, A. (2004). Elevated triiodothyronine in psychopathy-possible physiological mechanisms. Journal of Neural Transmission, 111, 739-744.
150. Soler, J., Pascual, J. C., Campins, J., Barrachina, J., Puigdemont, D., Alvarez, E., & Pérez, V. (2005). Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry, 162, 1221-1224.
151. Soloff, P. H. (2000). Psychopharmacology of borderline personality disorder. Psychiatric Clinics of North America, 23, 169-192.
152. Soloff, P. H., Cornelius, J., George, A., Nathan, S., Perel, J. M., &
153. Soloff, P. H., George, A., Nathan, R. S., Schulz, P. M., Cornelius, J. R., Herring, J., & Perel, J. M. (1989). Amitriptyline versus haloperidol in borderlines: Final outcomes and predictors of response. Journal of Clinical Psychopharmacology, 9, 238-246.
154. Soloff, P. H., George, A., Nathan, R. S., Schulz, P. M., & Perel, J. M. (1986a). Paradoxical effects of amitriptyline on borderline patients. American Journal of Psychiatry, 143, 1603-1605.
155. Soloff, P. H., George, A., Nathan, R. S., Schulz, P. M., & Perel, J. M. (1987). Behavioral dyscontrol in borderline patients treated with amitriptyline. Psychopharmacology Bulletin, 23, 177-181.
156. Soloff, P. H., George, A., Nathan, R. S., Schulz, P. M., Ulrich, R. F., & Perel, J. M. (1986b). Amitriptyline and haloperidol in unstable and schizotypal borderline disorders. Psychopharmacology Bulletin, 22, 177-182.
157. Soloff, P. H., George, A., Nathan, R. S., Schulz, P. M., Ulrich, R. F., & Perel, J. M. (1986c). Progress in pharmacotherapy of borderline disorders. Archives of General Psychiatry, 43, 691-697.
158. Stuart, S., Simons, A. D., Thase, M. E., & Pilkonis, P. (1992). Are personality assessments valid in acute major depression? Journal of Affective Disorders, 24, 281-290.
159. Sullivan, P. F., Joyce, P. R., &Mulder, R. T. (1994). Borderline personality disorder in major depression. Journal of Nervous and Mental Disease, 182, 508-516.
160. Thase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005). Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Journal of Clinical Psychiatry, 66, 974-981.
161. Thurauf, N. J., & Washeim, H. A. (2000). The effects of exogenous analgesia in a patient with borderline personality disorder (BPD). and severe self-injurious behavior. European Journal of Pain, 4, 107-109.
162. Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., Evans, A. R., Beymer, K., Dube, S., Tollefson G. D., & Breier, A. (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry, 60, 1079-1088.
163. Traskman, L., Asberg, M., Bertilsson, L., & Sjostrand, L. (1981). Monoamine metabolites in CSF and suicidal behavior. Archives of General Psychiatry, 38, 631-636.
164. Trestman, R. L., Keefe, R. S., Mitropoulou, V., Harvey, P. D., deVegvar, M. L., Lees-Roitman, S., Davidson, M., Aronson, A., Silverman, J., & Siever L. J. (1995). Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Research, 59, 127-136.
165. Tritt, K., Nickel, C., Lahmann, C., Leiberich, P. K., Rother, W. K., Loew, T. H., & Nickel, M. K. (2005). Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebocontrolled study. Journal of Psychopharmacology, 19, 287-291.
166. Vaillant, G. E., & Perry, J. C. (1985). Personality disorders. In H. I. Kaplan & B. J. Sadock (Eds.), Comprehensive textbook of psychiatry, 4th edn (pp. 958-986). Baltimore: Williams & Wilkins.
167. Verkes, R. J, Van der Mast, R. C, Hengeveld, M. W., Tuyl, J. P, Zwinderman, A. H., & Van Kempen, G. M. (1998). Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. American Journal of Psychiatry, 155, 543-547.
168. Virkkunen, M., Rawlings, R., Tokola, R., Poland, R. E., Guidotti, A., Nemeroff, C., Bissette, G., Kalogeras, K., Karonen, S. L., & Linnoila, M. (1994). CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Archives of General Psychiatry, 51, 20-27.
169. Walsh, S. L., Strain, E. C., Abreu, M. E., & Bigelow, G. E. (2001). Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berlin), 157, 151-162.
170. Westen, D. (1997). Divergences between clinical and research methods for assessing personality disorders: Implications for research and the evolution of axis II. American Journal of Psychiatry, 154, 895-903.
171. Widiger, T. A., & Shea, T. (1991). Differentiation of axis I and axis II disorders. Journal of Abnormal Psychology, 100, 399-406.
172. Winstanley, C. A., Theobald, D. E., Dalley, J. W., Glennon, J. C., & Robbins, T. W. (2004). 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: Interactions with global 5-HT depletion. Psychopharmacology (Berlin), 176, 376-385.
173. Yu, Y. W.-Y., Tsai, S.-J., Chen, T.-J., Lin, C.-H., & Hong, C.-J. (2002). Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Molecular Psychiatry, 7, 1115-1119.
174. Zanarini, M. C., & Frankenburg, F. R. (2001). Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry, 62, 849-854.
175. Zanarini, M. C., & Frankenburg, F. R. (2003). Omega-3 fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. American Journal of Psychiatry, 160, 167-169.
176. Zanarini, M. C., Frankenburg, F. R., & Parachini, E. A. (2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry, 7, 903-907.
177. Zimmerman, M. (1994). Diagnosing personality disorders. A review of issues and research methods. Archives of General Psychiatry, 51, 225-245.